Immunoglobulin E and bullous pemphigoid

被引:40
作者
Cozzani, Emanuele [1 ]
Gasparini, Giulia [1 ]
Di Zenzo, Giovanni [2 ]
Parodi, Aurora [1 ]
机构
[1] Univ Genoa, Di S Sal, Dermatol Sect, San Martino Policlin Hosp, I-16132 Genoa, Italy
[2] IDI IRCCS, Mol & Cell Biol Lab, Fdn Luigi Maria Monti, Rome, Italy
关键词
bullous pemphigoid; Th2; anti-BP230 and anti-BP180 IgE; omalizumab; FC-EPSILON-RI; LINKED-IMMUNOSORBENT-ASSAY; MEMBRANE ZONE ANTIBODIES; SERUM IGE LEVELS; BLISTER FLUID; MAST-CELLS; DISEASE-ACTIVITY; AUTOIMMUNE-DISEASE; CIRCULATING IGE; ELEVATED LEVELS;
D O I
10.1684/ejd.2018.3366
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Clinical features and histological findings in bullous pemphigoid (BP) suggest a Th2-oriented inflammatory reaction, especially in the early stages of the disease. Elevated total serum IgE levels, blood eosinophilia, and elevated serum levels of different soluble inflammatory Th2 response mediators have been described in large cohorts of patients with classic clear-cut BP manifestations. Direct immunofluorescence, indirect immunofluorescence, and anti-BP230 and anti-BP180 IgE ELISA testing show self-reactive IgE autoantibodies in a consistent number of BP patients. Both IgE autoantibodies and a Th2-oriented immune response may play a role in the initial phases of BP and atypical cases of BP, such as severe erythematous and urticarial forms of BP, as well as blister formation. Two recently reported experimental murine models employing IgE autoantibodies against BP180 have been reported and the successful treatment of bullous pemphigoid with the anti-IgE antibody, omalizumab, supports the roles played by IgE autoantibodies in BP pathogenesis.
引用
收藏
页码:440 / 448
页数:9
相关论文
共 117 条
[61]   Possible correlation of IgE autoantibody to BP180 with disease activity in bullous pemphigoid [J].
Kamiya, Koji ;
Aoyama, Yumi ;
Noda, Kazuyo ;
Miyake, Tomoko ;
Yamaguchi, Mari ;
Hamada, Toshihisa ;
Tokura, Yoshiki ;
Iwatsuki, Keiji .
JOURNAL OF DERMATOLOGICAL SCIENCE, 2015, 78 (01) :77-79
[62]  
Kasahara-Imamura M, 2001, INT J MOL MED, V7, P249
[63]   TRANSFER-FACTOR TREATMENT IN BULLOUS PEMPHIGOID - IMPAIRED T-CELL FUNCTION [J].
KHAN, A ;
AYYAR, R ;
MICHAELSON, JD ;
WEAVER, RE ;
HILL, NO .
DERMATOLOGICA, 1980, 161 (04) :243-249
[64]  
Kippes W, 1999, HAUTARZT, V50, P866, DOI 10.1007/s001050051001
[65]  
Kita H, 1999, J IMMUNOL, V162, P6901
[66]   The predominance of IgG4 in prodromal bullous pemphigoid [J].
Lamb, Philina M. ;
Patton, Timothy ;
Deng, Jau-Shyong .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2008, 47 (02) :150-153
[67]   Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils [J].
Lin, H ;
Boesel, KM ;
Prussin, C ;
Foster, B ;
Romero, FA ;
Townley, R ;
Casale, TB .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 113 (02) :297-302
[68]   Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid [J].
Liu Bing ;
Zhou Xiping ;
Li Li ;
Peng Jun ;
Wang Yi-Xia ;
Yang Min ;
Liu Qing ;
Sun Qiu-Ning ;
Jin Hong-Zhong ;
Zuo Ya-Gang .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2015, 307 (09) :849-854
[69]  
Liu Bing, 2013, Zhonghua Yi Xue Za Zhi, V93, P2244
[70]   CLINICAL VARIANTS OF PEMPHIGOID [J].
LIU, HNH ;
SU, WPD ;
ROGERS, RS .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1986, 25 (01) :17-27